Malignant glioma
Adult: As hydrochloride: 2-3 mg/kg or 90-100 mg/m2 as a single dose by slow IV inj at intervals of 6 wk according to haematological response.
Indications and Dosage
Intravenous
Malignant glioma Adult: As hydrochloride: 2-3 mg/kg or 90-100 mg/m2 as a single dose by slow IV inj at intervals of 6 wk according to haematological response.
|
Contraindications
Pregnancy and lactation.
|
Special Precautions
Child. Renal or hepatic impairment, haemorrhagic syndrome, infectious diseases. Monitor blood counts and liver function.
|
Adverse Reactions
Leukopenia, iron-deficiency anaemia, anorexia, nausea, vomiting, diarrhoea, stomatitis, headache, dizziness, convulsions, weakness, fatigue, haemorrhagic symptoms, interstitial pneumonitis, increased body temperature, alopecia, rash, increased transaminases.
Potentially Fatal: Delayed and cumulative bone marrow depression. |
Drug Interactions
Additive bone marrow suppression with other cytotoxic drugs e.g. vincristine, doxorubicin, mitomycin.
|
Action
Description:
Mechanism of Action: Nimustine, a nitrosourea, is an alkylating antineoplastic agent. It interferes with normal DNA function by alkylating and cross-linking the strands of DNA and possibly by protein modification. |
MIMS Class
|